| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
|
J Clin Oncol
|
2003
|
12.48
|
|
2
|
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
|
Lancet Oncol
|
2009
|
9.39
|
|
3
|
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
|
J Clin Oncol
|
2004
|
6.59
|
|
4
|
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
|
JAMA
|
2006
|
6.45
|
|
5
|
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.
|
J Natl Cancer Inst
|
2006
|
6.41
|
|
6
|
Cardiac dysfunction in the trastuzumab clinical trials experience.
|
J Clin Oncol
|
2002
|
6.09
|
|
7
|
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.
|
N Engl J Med
|
2004
|
4.84
|
|
8
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
Mayo Clin Proc
|
2015
|
4.70
|
|
9
|
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
|
J Clin Oncol
|
2008
|
4.09
|
|
10
|
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
|
Nat Genet
|
2013
|
4.03
|
|
11
|
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
|
J Clin Oncol
|
2008
|
3.54
|
|
12
|
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
|
JAMA
|
2005
|
3.43
|
|
13
|
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
|
Breast Cancer Res Treat
|
2011
|
2.73
|
|
14
|
Developing a cancer-specific geriatric assessment: a feasibility study.
|
Cancer
|
2005
|
2.57
|
|
15
|
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
|
Clin Cancer Res
|
2011
|
2.43
|
|
16
|
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
|
J Clin Oncol
|
2008
|
2.28
|
|
17
|
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
|
Proc Natl Acad Sci U S A
|
2011
|
2.18
|
|
18
|
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.
|
Clin Cancer Res
|
2009
|
2.10
|
|
19
|
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
|
Breast Cancer Res
|
2003
|
2.09
|
|
20
|
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
|
J Clin Oncol
|
2012
|
2.07
|
|
21
|
The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999.
|
Cancer
|
2005
|
1.86
|
|
22
|
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
|
J Clin Oncol
|
2004
|
1.83
|
|
23
|
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
|
J Clin Oncol
|
2008
|
1.78
|
|
24
|
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up.
|
J Clin Oncol
|
2008
|
1.75
|
|
25
|
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
|
J Clin Oncol
|
2003
|
1.64
|
|
26
|
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
|
J Clin Oncol
|
2007
|
1.59
|
|
27
|
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
|
Cancer Res
|
2002
|
1.59
|
|
28
|
Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.
|
J Am Geriatr Soc
|
2006
|
1.57
|
|
29
|
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.
|
Cancer Res
|
2006
|
1.55
|
|
30
|
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
|
Clin Cancer Res
|
2012
|
1.50
|
|
31
|
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
|
J Clin Oncol
|
2010
|
1.44
|
|
32
|
Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiation.
|
Cancer
|
2011
|
1.38
|
|
33
|
EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange.
|
J Biol Chem
|
2007
|
1.36
|
|
34
|
Factors influencing treatment patterns of breast cancer patients age 75 and older.
|
Crit Rev Oncol Hematol
|
2003
|
1.35
|
|
35
|
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.
|
Cancer Res
|
2005
|
1.32
|
|
36
|
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
|
J Clin Oncol
|
2002
|
1.32
|
|
37
|
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
|
Cancer
|
2005
|
1.31
|
|
38
|
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.
|
J Clin Oncol
|
2010
|
1.27
|
|
39
|
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
|
Clin Breast Cancer
|
2011
|
1.11
|
|
40
|
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.
|
Breast Cancer Res Treat
|
2006
|
1.11
|
|
41
|
Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.
|
J Clin Oncol
|
2011
|
1.11
|
|
42
|
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
|
Breast Cancer Res Treat
|
2013
|
1.10
|
|
43
|
Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists.
|
Crit Rev Oncol Hematol
|
2006
|
1.09
|
|
44
|
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
|
Breast Cancer Res Treat
|
2005
|
1.08
|
|
45
|
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.
|
Lancet Oncol
|
2012
|
1.08
|
|
46
|
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
|
Breast Cancer Res
|
2013
|
1.03
|
|
47
|
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
|
Clin Breast Cancer
|
2006
|
1.02
|
|
48
|
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
|
Clin Cancer Res
|
2006
|
1.02
|
|
49
|
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.
|
Cancer Prev Res (Phila)
|
2012
|
1.01
|
|
50
|
The taxane limbo: how low can we go?
|
J Natl Cancer Inst
|
2008
|
1.01
|
|
51
|
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
|
Breast Cancer Res Treat
|
2011
|
1.01
|
|
52
|
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
|
J Clin Oncol
|
2002
|
1.00
|
|
53
|
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.99
|
|
54
|
Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
|
Cancer
|
2004
|
0.99
|
|
55
|
Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy.
|
Cancer
|
2004
|
0.98
|
|
56
|
Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription.
|
J Biol Chem
|
2008
|
0.97
|
|
57
|
Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction.
|
Radiother Oncol
|
2010
|
0.96
|
|
58
|
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
|
Breast Cancer Res Treat
|
2006
|
0.95
|
|
59
|
A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.
|
Clin Cancer Res
|
2012
|
0.93
|
|
60
|
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
|
Clin Cancer Res
|
2007
|
0.93
|
|
61
|
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
|
J Clin Oncol
|
2003
|
0.92
|
|
62
|
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
|
J Clin Oncol
|
2010
|
0.91
|
|
63
|
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).
|
Ann Surg
|
2015
|
0.91
|
|
64
|
Malignant lesion segmentation in contrast-enhanced breast MR images based on the marker-controlled watershed.
|
Med Phys
|
2009
|
0.90
|
|
65
|
Follow-up care of breast cancer survivors.
|
Crit Rev Oncol Hematol
|
2003
|
0.90
|
|
66
|
Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
|
Cancer
|
2012
|
0.89
|
|
67
|
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy.
|
J Am Geriatr Soc
|
2006
|
0.88
|
|
68
|
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
|
J Clin Oncol
|
2002
|
0.88
|
|
69
|
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
|
Clin Breast Cancer
|
2006
|
0.88
|
|
70
|
Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901.
|
J Cancer Surviv
|
2014
|
0.85
|
|
71
|
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
|
J Clin Oncol
|
2008
|
0.85
|
|
72
|
BRCA mutations in women with ductal carcinoma in situ.
|
Clin Cancer Res
|
2007
|
0.85
|
|
73
|
Breast cancer.
|
J Natl Compr Canc Netw
|
2005
|
0.85
|
|
74
|
Web based pathology assessment in RTOG 98-04.
|
J Clin Pathol
|
2014
|
0.84
|
|
75
|
Dose-dense chemotherapy for breast cancer: what does the future hold?
|
Future Oncol
|
2010
|
0.84
|
|
76
|
Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.
|
Drugs Aging
|
2005
|
0.83
|
|
77
|
Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection.
|
Cancer
|
2011
|
0.83
|
|
78
|
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
|
Breast Cancer Res Treat
|
2008
|
0.81
|
|
79
|
Bevacizumab in metastatic breast cancer: when may it be used?
|
Ther Adv Med Oncol
|
2011
|
0.80
|
|
80
|
Screening chest imaging studies are not effective in the follow-up of breast cancer patients.
|
J Oncol Manag
|
2003
|
0.80
|
|
81
|
Health policy: Upholding the Affordable Care Act--implications for oncology.
|
Nat Rev Clin Oncol
|
2012
|
0.80
|
|
82
|
Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
|
Breast J
|
2005
|
0.80
|
|
83
|
Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.79
|
|
84
|
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
|
Clin Breast Cancer
|
2004
|
0.78
|
|
85
|
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
|
Clin Cancer Res
|
2007
|
0.78
|
|
86
|
Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
|
Drugs Aging
|
2005
|
0.78
|
|
87
|
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
|
Breast Cancer Res Treat
|
2015
|
0.78
|
|
88
|
Aromatase inhibitors in breast cancer: an update.
|
Cancer Control
|
2003
|
0.78
|
|
89
|
Bone scans, bisphosphonates, and a lack of acute changes within the mandible.
|
J Oral Maxillofac Surg
|
2010
|
0.76
|
|
90
|
cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
|
Mutat Res
|
2008
|
0.76
|
|
91
|
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.
|
Clin Breast Cancer
|
2010
|
0.75
|
|
92
|
Breast cancer and leukemia: the forest for the trees?
|
Ann Surg Oncol
|
2002
|
0.75
|
|
93
|
Epoetin alfa: to give or not to give.
|
J Natl Cancer Inst
|
2013
|
0.75
|
|
94
|
Can granulocyte-colony stimulating factor worsen anemia?
|
J Clin Oncol
|
2006
|
0.75
|
|
95
|
Testing chemotherapy for breast cancer: timing is everything.
|
J Clin Oncol
|
2005
|
0.75
|
|
96
|
Dose-dense chemotherapy with trastuzumab is an appropriate option.
|
J Clin Oncol
|
2008
|
0.75
|
|
97
|
Recent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium.
|
Clin Adv Hematol Oncol
|
2011
|
0.75
|
|
98
|
Adjuvant chemotherapy for primary breast cancer.
|
Curr Oncol Rep
|
2005
|
0.75
|
|
99
|
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'.
|
Breast Cancer Res Treat
|
2005
|
0.75
|
|
100
|
Important advances in the treatment of breast cancer.
|
Oncology (Williston Park)
|
2012
|
0.75
|
|
101
|
Expedition Inspiration Fund for Breast Cancer Research Meeting 2003.
|
Breast Cancer Res Treat
|
2003
|
0.75
|
|
102
|
Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.
|
Clin Breast Cancer
|
2009
|
0.75
|